Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway

Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Agonists of the glucagon-like peptide-1 receptor (GLP-1R), currently approved to treat type 2 diabetes, hold promise to improve steatosis and even steatohepatitis. However, due to their pleiotropic effects, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalifa, Olfa, AL-Akl, Neyla S., Errafii, Khaoula, Arredouani, Abdelilah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828858/
https://www.ncbi.nlm.nih.gov/pubmed/35140289
http://dx.doi.org/10.1038/s41598-022-06143-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828858/
https://www.ncbi.nlm.nih.gov/pubmed/35140289
http://dx.doi.org/10.1038/s41598-022-06143-5

Ejemplares similares